Sorry, you need to enable JavaScript to visit this website.

HALCION®, CIV (triazolam) Drug Interactions


7.1 Drugs Having Clinically Important Interactions with Halcion

Table 2 includes clinically significant drug interactions with Halcion [see Clinical Pharmacology (12.3)].

Table 2: Clinically Important Drug Interactions with Halcion
Clinical implicationThe concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.
Prevention or managementLimit dosage and duration of concomitant use of Halcion and opioids, and monitor patients closely for respiratory depression and sedation [see Warnings and Precautions (5.1)].
ExamplesMorphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.
CNS Depressants
Clinical implicationTriazolam produces additive CNS depressant effects when co-administered with other CNS depressants.
Prevention or managementLimit dosage and duration of Halcion during concomitant use with CNS depressants.
ExamplesPsychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs which themselves produce CNS depression.
Strong Inhibitors of CYP 3A
Clinical implicationConcomitant use of Halcion with strong CYP3A inhibitors has a profound effect on the clearance of Halcion, resulting in increased concentrations of triazolam and increased risk of adverse reactions [see Clinical Pharmacology (12.3)].
Prevention or managementDo not administer Halcion with a strong CYP3A4 inhibitor [see Contraindications (4), Warnings and Precautions (5.7)].
ExamplesKetoconazole, clarithromycin, grapefruit juice, itraconazole, nefazodone, and several HIV protease inhibitors (e.g. ritonavir, indinavir, nelfinavir, saquinavir and lopinavir).
Moderate and Weak Inhibitors of CYP 3A
Clinical implicationConcomitant use of Halcion with moderate or weak inhibitors of CYP3A inhibitors may increase the concentrations of Halcion, resulting in increased risk of adverse reactions [see Clinical Pharmacology (12.3)].
Prevention or managementUse with caution and consider appropriate dose reduction of HALCION when coadministered with moderate and weak CYP3A inhibitors [see Warnings and Precautions (5.7)].
ExamplesMacrolide antibiotics (such as erythromycin), cimetidine, isoniazid, oral contraceptives, ranitidine.
Interactions Based on Experience with Other Benzodiazepines or in vitro Studies with Triazolam
Clinical implicationAvailable data from clinical studies of benzodiazepines other than triazolam, from in vitro studies with triazolam, or from in vitro studies with benzodiazepines other than triazolam suggest a possible drug interaction with triazolam [see Clinical Pharmacology (12.3)].
Prevention or managementCaution is recommended during coadministration of Halcion with any of these drugs. [see Warnings and Precautions (5.7)].
ExamplesFluvoxamine, diltiazem, verapamil, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event


Please enter your search term(s) for HALCION®, CIV